Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18793892 | 0.98 | CYP2C9 (0.35) | ANO1LMNADPP4CYP2C19CYP2C9 | |
| SCHEMBL18219589 | 0.93 | ANO1 (0.36) | ANO1LMNACYP2C9MEN1KMT2A | |
| SCHEMBL828036 | 0.89 | — | — | |
| SCHEMBL24974708 | 0.83 | LMNA (0.49) | ANO1LMNADPP4HDAC3HDAC1 | |
| SCHEMBL8689464 | 0.83 | LMNA (0.49) | ANO1LMNADPP4HDAC3HDAC1 | |
| SCHEMBL5143779 | 0.83 | DPP4 (0.35) | ANO1LMNADPP4CYP2C19MEN1 | |
| SCHEMBL852232 | 0.83 | HDAC3 (0.37) | ANO1LMNADPP4MEN1KMT2A | |
| SCHEMBL11336001 | 0.81 | ALDH1A1 (0.35) | ANO1LMNADPP4MEN1KMT2A | |
| SCHEMBL11341028 | 0.81 | ALDH1A1 (0.35) | ANO1LMNADPP4MEN1KMT2A | |
| SCHEMBL8399442 | 0.81 | DPP4 (0.34) | ANO1LMNADPP4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5780473-A | Substituted biphenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-14 | — | — | US | claimed |
| US-11820758-B2 | NEK6 kinase inhibitors useful for the treatment of solid tumors | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2023-11-21 | — | — | US | disclosed |
| US-11820758-B2 | NEK6 kinase inhibitors useful for the treatment of solid tumors | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2023-11-21 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-20210147395-A1 | NEK6 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF SOLID TUMORS | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2021-05-20 | — | — | US | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| EP-2780337-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20150284371-A1 | HETEROCYCLE-BISAMIDE INHIBITORS OF SCAVENGER RECEPTOR BI | THE BROAD INSTITUTE, INC. | 2015-10-08 | — | — | US | disclosed |
| US-5780473-A | Substituted biphenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147395-A1 | NEK6 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF SOLID TUMORS | NEK4, NEK2, NEK1 | ANO1 4048/4885LMNA 1561/4885DPP4 4008/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | ANO1 1906/4885LMNA 816/4885DPP4 4822/4885 |
| US-20150284371-A1 | HETEROCYCLE-BISAMIDE INHIBITORS OF SCAVENGER RECEPTOR BI | SCARB1, MSR1, LDLR | ANO1 3326/4885LMNA 1941/4885DPP4 2848/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | ANO1 1951/4885LMNA 600/4885DPP4 4827/4885 |
| US-11820758-B2 | NEK6 kinase inhibitors useful for the treatment of solid tumors | NEK4, NEK2, NEK1 | ANO1 4048/4885LMNA 1561/4885DPP4 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.